小续命汤治疗急性脑梗死的系统评价  

Systematic Review and Meta-analyses of Xiaoxuming Decoction on Acute Ischemic Stroke

作　　者：万芳竹 赵静[2] 崔德芝[3] 鞠建庆[2] 

机构地区：[1]山东大学医学院,山东济南250012 [2]山东中医药大学,山东济南250355 [3]山东中医药大学附属医院,山东济南250011

出　　处：《中国中医急症》2015年第5期791-793,共3页Journal of Emergency in Traditional Chinese Medicine

基　　金：山东省中医药科技发展计划项目(2005-195)

摘　　要：目的系统评价小续命汤治疗急性脑梗死的临床疗效和安全性。方法搜集小续命汤治疗急性脑梗死的随机对照试验,按照Cochrane协作网推荐的方法评估纳入研究的偏倚风险,提取相关数据,应用Rev Man5.3软件完成异质性检验,Meta分析,敏感性分析,倒漏斗图分析等相关统计分析。结果共纳入9项合格研究,共计631例患者,纳入研究均存在较高的方法学偏倚风险,Meta分析结果显示联用小续命汤与单纯常规西医治疗相比临床总有效率RR=1.15,95%CI[1.08,1.23],神经功能缺损评分MD=-3.52,95%CI[-4.45,-2.59],结果有统计学意义,敏感性分析提示该结果稳定性较好;倒漏斗图分析显示不对称;未见小续命汤不良反应报道。结论现有研究证据表明小续命汤可提高急性脑梗死的临床疗效,且安全性良好,但由于纳入研究的偏倚风险较高,尚需要开展样本量充足、设计合理、执行严格的临床试验进行验证。Objective： To systematically assess the efficacy of Xiaoxuming Decoction on acute ischemic stroke.Methods： Randomized controlled trials of Xiaoxuming Decoction on acute ischemic stroke were retrieved. The risk of bias of included studies was assessed according to the criteria recommended by the Cochrane Handbook for Systematic Reviews of interventions. Such statistical analyses as heterogeneity analysis,meta-analyses,sensitivity analyses and funnel plot analyses were performed using the Review Manager 5.3 software. Results： 9 qualified trials were included. The risk of bias was generally high. Meta analyses showed that Xiaoxuming Decoction on acute ischemic stroke can improve clinical effective rate,with RR=1.15,95%CI[1.08,1.23],can lower NIHSS,with MD=-3.52,95%CI [-4.45,-2.59]. Funnel plot was asymmetry. No adverse reaction was reported. Conclusion：Current evidence indicates that treating acute ischemic stroke with Xiaoxuming Decoction can improve the clinical efficacy. Due to the low quality of included studies,clinical trials with adequate samples,rational design and strict execution should be carried out to provide more reliable evidence.

关 键 词：急性脑梗死 小续命汤 随机对照试验 系统评价 META分析 

分 类 号：R743.33[医药卫生—神经病学与精神病学]